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The invasive nature of cancers in general, and malignant gliomas in particular, is a major clinical problem rendering
tumors incurable by conventional therapies. Using a novel invasive glioma mouse model established by serial in vivo
selection, we identified the p75 neurotrophin receptor (p75
NTR) as a critical regulator of glioma invasion. Through a
series of functional, biochemical, and clinical studies, we found that p75
NTR dramatically enhanced migration and
invasion of genetically distinct glioma and frequently exhibited robust expression in highly invasive glioblastoma
patient specimens. Moreover, we found that p75
NTR-mediated invasion was neurotrophin dependent, resulting in the
activation of downstream pathways and producing striking cytoskeletal changes of the invading cells. These results
provide the first evidence for p75
NTR as a major contributor to the highly invasive nature of malignant gliomas and
identify a novel therapeutic target.
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Introduction
Malignant gliomas are diffuse, highly invasive, and often
multifocal tumors that have a dismal prognosis, with a
median survival of only 1 y and ‘‘long-term survivors’’ (i.e.,
surviving  3 y) are rare [1,2]. A major barrier to effective
malignant glioma treatment is their highly invasive nature;
they extend tendrils of tumor several centimeters away from
the main tumor mass, which render these tumors incurable by
local therapies such as surgery or radiotherapy [3]. Ninety-
ﬁve percent of gliomas recur within 2.5 cm of the resection
margin, which contains invasive cells that act as a ‘‘disease
reservoir’’ and elude current treatments [4]. Glioma cells do
this by becoming distinct from their noninvasive counter-
parts. Speciﬁcally, they activate a number of coordinate
cellular programs, which include those necessary for migra-
tion (e.g., motility) and invasion (e.g., extracellular matrix
degradation) [5] and also a number of pathways (e.g., reduced
proliferation, marked resistance to apoptosis) [4,6,7] which
render the invasive cells highly resistant to conventional
treatments. A detailed understanding of the mechanisms
underlying this invasive behavior is essential for the develop-
ment of effective therapies.
Although in their infancy, attempts to identify genes
involved in glioma invasion have used a number of
techniques, including the isolation of invasive cells from
human cell lines in vitro [6,7], the use of organotypic brain
slice cultures [8], and the collection of tumor and invasive
cells from frozen glioblastoma patient specimens using laser
capture microdissection [9–11]. Although each method has
been successful in its own right, none of these models have
been ideal or comprehensive for discovering the underlying
mechanisms of invasion. New models or alternative strategies
are needed. We have therefore undertaken the approach of
serial in vivo selection to identify genes important for the
invasive behavior of malignant glioma. Similar strategies have
been used to effectively identify mechanisms underlying the
metastatic behavior of both melanoma and breast tumors
[12,13]. Using this approach, we isolated highly invasive
glioma cells from a relatively noninvasive human malignant
glioma. Gene expression proﬁles comparing these two tumor
cell populations identiﬁed the p75 neurotrophin receptor
(p75
NTR) as an important and potent mediator of invasion in
human glioma.
p75
NTR is a transmembrane glycoprotein and a member of
the tumor necrosis factor (TNF) superfamily that was
originally isolated as a nerve growth factor (NGF) receptor,
but has since been shown to bind both the mature and
precursor forms of the neurotrophin family of ligands (brain-
derived neurotrophin factor [BDNF], neurotrophin-3 [NT-3],
and neurotrophin-4/5 [NT-4/5]) [14–18]. In neurons, p75
NTR is
coexpressed with a second group of neurotrophin receptors,
the tropomysin receptor kinases (Trks). It has become
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mediate neuronal survival and p75
NTR causes neuronal cell
death is too narrow a view [19–22]. Rather, there is a growing
appreciation that p75
NTR, like other members in the TNF
superfamily, mediates a very broad range of cellular
functions, depending on the cell context and the repertoire
of co-receptors that exist (e.g., Trks [23], Nogo receptor [24],
and sortilin [25]). In neurons, p75
NTR has been shown to
increase [26,27] or inhibit [28] axon growth, reduce [29] or
promote [30,31] neuronal cell death, and is either necessary
[32] or not required [33] for inhibition of neuronal
regeneration. These apparent discrepancies are not conﬁned
to neurons; p75
NTR has also been shown to both inhibit [34]
and promote [26,35] Schwann cell migration during develop-
ment. Even though p75
NTR does not contain any catalytic
activity, it interacts with several proteins that help transmit
signals required for its various functions. Neurotrophin
engagement of p75
NTR controls the activity of the small
GTPase RhoA, providing a direct link from the receptor to
modulating cellular architecture. As is the case for pheno-
typic responses, RhoA has been shown to be activated or
inhibited depending on cellular context [27,28,34,36–38].
Reports have hinted at roles for p75
NTR in growth [39] and
apoptosis [40] of glioma cells; however, data presented here
support a much different role for p75
NTR—that of mediating
glioma cell invasion.
Results
Establishment of a Malignant Glioma Mouse Model to
Study the Molecular Determinants of Glioma Invasion
One of the problems in xenotransplanting human glioma
cells into the brains of immunocompromised mice is that the
resulting tumors are circumscribed, with very little cell
inﬁltration into the brain parenchyma [41]. To generate an
orthotopic model that more closely mimics the human
disease and allows for the identiﬁcation of molecular
determinants of glioma invasion in a global and unbiased
manner, we used an in vivo–selection procedure to select for
highly invasive human glioma cells (Figure 1A). We isolated
highly invasive glioma cells from the noninvasive human
malignant glioma cell line U87 expressing green ﬂuorescent
protein (GFP) (U87GFP) and a neomycin resistance gene.
Expression of these genes afforded us the ability to isolate the
rare glioma cell that migrated away from the primary tumor
site. These ‘‘invasive’’ cells were grown and expanded in tissue
culture, and reintroduced into the brains of immunocom-
promised mice where they formed highly inﬁltrative tumors
with poorly deﬁned edges (Figure 1B). These extremely
invasive cells were found vast distances from the main tumor
mass, with GFP-positive tumor cells readily identiﬁable in the
contralateral hemisphere. In clear contrast, reimplantation of
the noninvasive ‘‘tumor’’ cells led to the formation of large
tumors with sharply demarcated edges (Figure 1B). Using this
model, we identiﬁed gene expression differences between the
noninvasive and highly invasive in vivo–selected glioma cells.
RNA extracted from tumor and invasive populations was
used to prepare labeled cDNA that was hybridized to 14,000-
gene human oligonucleotide microarrays (produced by the
Southern Alberta Microarray Facility, University of Calgary).
Genes up- or down-regulated in the invasive population were
compared to the tumor population, and genes that showed
consistent gene expression changes of 2-fold or greater are
outlined in Figure 2A. To ensure the integrity of the
microarray data, we chose seven arbitrary genes for valida-
tion, the expression of ﬁve of which are shown in Figure 2B
and 2C. Semiquantitative real-time polymerase chain reac-
tion (RT-PCR) conﬁrmed the expression of all seven genes,
including granulocyte colony-stimulating factor (G-CSF),
interleukin-8 (IL-8), DZFKp434B204 (unknown hypothetical
protein), tissue inhibitor of metalloproteinases-3 (TIMP-3),
and p75
NTR (Figure 2B and 2C). The semiquantitative RT-
PCR indicates that our microarray data is an under-
representation of the fold changes in RNA expression. Based
on the reproducibility of the data, previous implication in
tumorigenesis in other cancers (e.g., melanoma and prostate)
[42–47], and the novelty of the ﬁnding in brain tumors, we
chose p75
NTR for further study. Importantly, we conﬁrmed
the up-regulation of p75
NTR was not only at the mRNA level,
but that a dramatic alteration in abundance of p75
NTR was
seen in the invading cells (Figure 2C). A number of invasive
lines were generated by serial in vivo selection and micro-
array analysis using a second independent U87 invasive line
validated the presence of p75
NTR by microarray that was
conﬁrmed by RT-PCR and Western blot (unpublished data).
In addition, using the in vivo–selection paradigm outlined in
Figure 1, we isolated both tumor and invasive cells from a
second human glioma cell line, U251N. These in vivo–selected
invasive U251N cells also expressed high levels of endogenous
p75
NTR (Figure S1).
In Vivo Selection Identifies p75
NTR as a Mediator of Glioma
Invasion
Although p75
NTR and its ligands, the neurotrophins, are
expressed throughout the nervous system, particularly during
development, a role for p75
NTR in central nervous system
tumors has not been described previously. We therefore
assessed whether the up-regulation of p75
NTR found in the
invasive glioma cells had a functional consequence (i.e.,
increased their migration and invasion). The noninvasive and
highly invasive cells were treated with the p75
NTR ligand NGF,
and migration and invasion were measured. The addition of
NGF to invasive cells signiﬁcantly increased the number of
cells able to invade through matrigel, but had no effect on the
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Author Summary
Gliomas are highly malignant and invasive tumors with tendrils that
extend far from the primary tumor site, rendering conventional
therapies ineffective and leading to an invariably poor prognosis. To
understand the molecular mechanisms underlying this invasive
behavior, we injected immunocompromised mice with human
gliomas and compared invasive cells, which left the primary tumor
site, to noninvasive cells, which remained at the site of injection. We
identified the neurotrophin receptor p75
NTR—which normally
functions during development to induce neurite outgrowth and
promote neuronal cell death—as an important regulator of glioma
invasion. We present the first evidence that this neurotrophin
receptor can also be a potent mediator of glioma invasion, and we
show that the expression of this receptor is sufficient to impart a
dramatic invasive behavior on genetically distinct tumors. These
data highlight a previously unknown function of this receptor and
suggest it may be a novel therapeutic target in the treatment of this
devastating cancer.invasive ability of the tumor cells (which had no detectable
p75
NTR; Figure 2D). Because neurotrophins are also ligands
for the Trk receptors, RT-PCR and immunoprecipitation
experiments were performed. No detectable mRNA or
protein for the Trk receptors was found in the invading
glioma cells (unpublished data). In addition, we tested the
effect of the unprocessed or proform of NGF (pro-NGF), a
high-afﬁnity ligand for p75
NTR [33,39] that is unable to
activate Trk [16]. Accordingly, treatment of the invasive cells
with cleavage-resistant pro-NGF enhanced their migration at
concentrations as low as 1 ng/ml while having no effect on the
tumor cells (Figure S2). Although we found that neurotrophin
could enhance invasion of the p75
NTR-positive invasive cells
(Figure 2D), we also observed a signiﬁcant increase in the
absence of ligand. Signals from p75
NTR can arise both in the
absence and presence of ligand; however, these signals often
evoke opposing biological responses. Because the outcome of
both neurotrophin-dependent and neurotrophin-independ-
ent signaling was the same, we considered the possibility that
the glioma cells were producing and secreting neurotro-
Figure 1. Serial In Vivo Selection Was Used to Isolate a Highly Invasive Glioma Population from a Noninvasive Human Malignant Glioma Cell Line
(A) The noninvasive human glioma cell line U87 stably expressing GFP (U87GFP) was implanted into the brains of SCID mice. Four to 6 wk later, the mice
were sacrificed. The ipsilateral side of the brain (containing a grossly visible tumor) was separated from the contralateral side (containing only isolated
invasive glioma cells [i.e., no macroscopically visible GFP-labeled tumor]), and both were grown in culture. These noninvasive (tumor) and highly
invasive glioma cells were reimplanted into additional mice, and the process was repeated to select for increasingly noninvasive or invasive glioma cells.
RNA extracted from the resulting invasive and tumor populations was used to prepare labeled cDNA that was hybridized to oligonucleotide
microarrays.
(B) Brains of SCID mice implanted with either tumor (left) or invasive (center and right) glioma cells. GFP visualization reveal the well-circumscribed
border of the reimplanted tumor cells, with no tumor cells being detected away from the main tumor mass (left). This is in sharp contrast to the highly
invasive border of the invasive tumors, where isolated small groups of glioma cells are found throughout the brain (center and right). Scale bars on GFP
images represent 125 lm (center) and 62 lm (right and left).
doi:10.1371/journal.pbio.0050212.g001
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NTR-Induced Invasion in GliomaFigure 2. Microarray Experiments Were Performed to Compare the Gene Expression Differences between the In Vivo–Selected Noninvasive (Tumor) and
Invasive Glioma Cells
(A) Table lists results from a representative set of lineage experiments. Four independent microarray experiments were performed, each containing a
pair of dye-flipped hybridizations. Genes that displayed consistent gene expression changes (.2-fold change in at least five out of eight hybridizations)
are listed. The indicated ratios represent the fold change in gene expression in the invasive compared to the noninvasive cells. Genes chosen for
validation are indicated in red.
(B and C) Seven genes were chosen for validation; the expression of five are shown. (B) RT-PCR confirmed the expression of granulocyte colony-
stimulating factor (G-CSF), interleukin-8 (IL-8), an unknown hypothetical protein DZFKp434B204 (DZFK), and tissue inhibitor of metalloproteinases-3
(TIMP-3) in the invasive population. Expression levels of GAPDH (unchanged) are shown for comparison. (C) RT-PCR and Western blot confirm
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expression of several neurotrophins and found that BDNF
was present in both the conditioned media and the cell lysate
of all glioma cells tested (unpublished data). Furthermore, we
found that the presence of p75
NTR shifted the localization of
BDNF from the conditioned media to the cell membrane
(Figure S3), supporting the notion of autocrine/paracrine
activation of the p75
NTR receptor.
To directly test the hypothesis that elevated expression of
p75
NTR is necessary for neurotrophin-induced glioma migra-
tion and invasion, we surveyed a panel of human glioma cell
lines for p75
NTR protein expression. We found that the
human glioma cell line SF767 endogenously expressed high
levels of p75
NTR, as detected by Western blot (Figure 3A) and
ﬂuorescence-activated cell-sorting (FACS) analysis (unpub-
lished data). Using RNA interference (RNAi), we down-
regulated p75
NTR in the SF767 cell line using an expression
vector containing a p75
NTR-speciﬁc small interfering ribonu-
cleic acid (siRNA) and conﬁrmed the down-regulation by RT-
PCR and Western blot (Figure 3A). A random, nonspeciﬁc
siRNA sequence was used as a control. Down-regulation of
p75
NTR levels in SF767 was sufﬁcient to reduce its migration
in vitro and rendered the cells nonresponsive to addition of
NGF in both migration and invasion assays (Figure 3B and
3C). Similarly, down-regulation of p75
NTR by siRNA in the
original in vivo–selected U87 invasive cells signiﬁcantly
blocked migration and invasion (Figure S4).
Since down-regulation of p75
NTR in SF767 cells and U87 in
vivo–selected invasive cells inhibited glioma invasion, we
assessed whether ectopic expression of p75
NTR alone was
sufﬁcient to increase glioma migration and invasion in a cell
line without detectable p75
NTR (the original U87 cell line). To
this end, we stably transfected the full-length cDNA of human
p75
NTR into the U87 glioma cell line, using stable transfection
of the empty pcDNA vector as a control. Expression levels of
p75
NTR in these cells were conﬁrmed by RT-PCR and Western
blot (Figure 3D). Expression of p75
NTR caused a signiﬁcant
increase in migration and invasion in vitro (Figure 3E and
3F). Treatment of these cells with NGF had no further
enhancement on their migration or invasion consistent with
the idea that when p75
NTR is expressed, an autocrine loop is
completed, leading to enhanced migration and invasion.
Expression of p75
NTR Increases Invasion In Vivo in
Genetically Distinct Glioblastomas
Malignant gliomas clinically show extensive inﬁltration
away from the main tumor and into the surrounding normal
brain tissue. To determine whether the expression of p75
NTR
was important for glioma cell invasion in vivo, we implanted
the U87 human glioma cell line ectopically expressing p75
NTR
into the brains of severe combined immunodeﬁciency (SCID)
mice. U87 cells stably transfected with the empty pcDNA
vector were implanted for comparison as a control. Twenty-
eight days after implantation, the mice were sacriﬁced and
the brains prepared for immunohistochemical staining using
antibodies directed against human nuclei and p75
NTR.
Implantation of U87 glioma cells stably transfected with
pcDNA led to the formation of well-circumscribed tumors
that were p75
NTR negative (Figure 4A). In sharp contrast,
implantation of U87 glioma cells stably expressing p75
NTR
resulted in the formation of tumors with highly inﬁltrative
edges (Figure 4B). Isolated p75
NTR-positive human glioma
cells could be detected in regions vastly distant from the main
tumor mass (Figure S5).
Because malignant gliomas are an extremely heterogeneous
group of tumors and the in vivo–selected U251N cells also
expressed high levels of p75 (Figure S1), we determined
whether the sole expression of p75
NTR was sufﬁcient to
impart an invasive phenotype, not only on the U87 cells, but
also on the genetically distinct U251N cells. U251N cells
ectopically expressing p75
NTR (U251Np75), along with empty
vector–transfected cells as a control (U251NpcDNA), were
implanted into the brains of SCID mice as described above.
As we have observed previously, the U251N control cell line
(U251NpcDNA) was inherently more invasive than
U87pcDNA in vivo, with ﬁnger-like projections extending
from the main tumor mass into the surrounding normal
brain (compare Figure 4A and 4C). Nevertheless, ectopic
expression of p75
NTR (U251Np75) dramatically enhanced the
inherent invasive ability, with p75
NTR-positive cells being
found at locations distinct from the main tumor mass
(compare Figure 4C and 4D). Thus, up-regulation of p75
NTR
is sufﬁcient to allow glioma cells of diverse genetic back-
grounds to invade into the surrounding normal brain.
Because p75
NTR can have effects on several physiological
responses, we also evaluated the effect of p75
NTR expression
on cell cycle, proliferation, and survival, and observed no
signiﬁcant change (unpublished data).
p75
NTR-Mediated Glioma Invasion Is Neurotrophin
Dependent
In order to test whether neurotrophin was important in the
invasive behavior of these cells, we constructed two p75
NTR
mutants, p75CRD
105 and p75CRD
130, containing a four–amino
acid insertion in the cysteine-rich domain (CRD) following
amino acids 105 and 130 (CRD 105 and CRD 130),
respectively. Insertions at these locations disrupt the normal
spacing of the cysteine residues within the164 ligand-binding
domain and create p75
NTR proteins that are unable to bind to
mature neurotrophin [48]. These constructs were stably
transfected into U87 glioma cells, and cell surface expression
for the mutant p75
NTR proteins was conﬁrmed by FACS
analysis (Figure 5A). To verify that the mutant p75
NTR do not
bind neurotrophin, BDNF expression in the conditioned
medium and total cell lysates of U87 cells expressing CRD
105
and CRD
130 were performed. Unlike the wild-type p75
NTR-
expressing glioma cells in which expression of p75
NTR causes
a shift in BDNF localization from the medium to the cell
lysate, cells expressing the mutant alleles (CRD
105 and CRD
130)
did not result in a shift of BDNF localization, conﬁrming that
expression of p75 in the invasive population (Inv) but not the tumor cell population (T). RT-PCR analysis of GAPDH levels and Western blot analysis of
pyruvate kinase levels are included as loading controls. Human dorsal root ganglia (DRG) were used as a positive control.
(D) Addition of NGF (200 ng/ml) enhanced the migratory ability of the invasive glioma cells in matrigel-coated invasion chambers, but had no significant
effect on invasion of the tumor cells. Values shown are the mean 6 SEM from three independent experiments. Triple asterisks (***) indicate p , 0.001
versus control (two-way ANOVA with Bonferroni post-tests).
doi:10.1371/journal.pbio.0050212.g002
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These cells were implanted into the brains of SCID mice and
allowed to grow for 21 d. The mice were sacriﬁced, and frozen
brain sections were stained with antibodies against human
nuclei (Figure 5C; brown color, top row) and human p75
NTR
(Figure 5C; brown color, bottom row). Disruption of the
neurotrophin binding capacity of p75
NTR results in tumors
with well-deﬁned borders similar to tumors formed by the
parental U87 glioma cells that do not express p75
NTR. These
data suggest that neurotrophin binding is required for
p75
NTR-mediated glioma invasion.
p75
NTR-Expressing Glioma Cells from Human Glioma
Surgical Specimens Show Enhanced Migration
The highly invasive nature of malignant gliomas has been a
substantial barrier in the treatment of patients with this
disease. Data presented here strongly suggest that p75
NTR,i n
a neurotrophin-dependent manner, is an important regu-
lator of glioma invasion. To clinically validate p75
NTR’s role
in glioma migration and invasion, and demonstrate its
relevance in malignant glioma patient specimens, we analyzed
the expression of p75
NTR in a panel of surgically resected
Figure 3. p75
NTR Induces Migration and Invasion In Vitro
(A) Down-regulation of p75
NTR using RNAi decreases glioma migration/invasion. RT-PCR (GAPDH used as a loading control) and Western blot (pyruvate
kinase used as a loading control) for p75
NTR confirm down-regulation of p75
NTR in the glioma cell line SF767 transfected with a p75-specific siRNA.
Untransfected cells, cells transfected with a random siRNA, and the in vivo–selected tumor and invasive cells are shown for comparison.
(B) Treatment with NGF (200 ng/ml) enhanced migration of SF767 cells transfected with the random (control) siRNA, but had no significant effect on
migration of SF767 cells in which p75
NTR expression was inhibited by p75
NTR-specific siRNA. Values shown are the mean 6 SEM from three independent
experiments. A single asterisk (*) indicates p , 0.05, and double asterisks (**) indicate p , 0.01 versus control-treated random siRNA-transfected cells;
triple asterisks (***) indicate p , 0.001 versus NGF-treated random siRNA-transfected cells (two-way ANOVA with Bonferroni post-tests).
(C) Treatment with NGF (200 ng/ml) enhanced invasion of SF767 cells transfected with random siRNA, but had no significant effect on invasion of SF767
cells in which p75
NTR expression was inhibited by p75
NTR-specific siRNA. Values shown are the mean 6 SEM from a single experiment. Similar results
were seen in two independent experiments. Double asterisks (**) indicate p , 0.01 versus control-treated random siRNA-transfected cells, and double
pluses (þþ) indicate p , 0.01 versus NGF-treated random siRNA-transfected cells (two-way ANOVA with Bonferroni post-tests).
(D) Ectopic expression of p75
NTR induces glioma migration/invasion. RT-PCR (GAPDH used as a loading control) and Western blot (pyruvate kinase used
as a loading control) for p75
NTR confirm expression of p75
NTR in U87 cells stably transfected with pcDNA3.1 encoding human p75
NTR (U87p75). Cells
stably transfected with the empty pcDNA3.1 vector (U87pcDNA), as well as in vivo–selected tumor and invasive cells are shown for comparison.
(E) Migration of U87 glioma cells is enhanced by ectopic expression of p75
NTR. No additional increase was seen following treatment with NGF (200 ng/
ml). Values shown are the mean 6 SEM from three independent experiments. Triple asterisks (***) indicate p , 0.001 versus pcDNA-transfected cells
(two-way ANOVA with Bonferroni post-tests).
(F) Similarly, invasion of U87p75 glioma cells in matrigel-coated invasion chambers was significantly increased compared to controls. No further increase
was seen with exogenous NGF (200 ng/ml). Values shown are the mean 6 SEM from four independent experiments. A single asterisk (*) indicates p ,
0.05, and double asterisks (**) indicate p , 0.01 versus pcDNA-transfected cells (two-way ANOVA with Bonferroni post-tests).
doi:10.1371/journal.pbio.0050212.g003
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NTR-Induced Invasion in Gliomatumor specimens and normal human brain using immuno-
histochemical staining (Figure 6A), RT-PCR, and Western blot
(Figure 6B). Expression of p75
NTR protein was detected in 20
of 40 human glioma patient specimens (50%) (one of 11 low-
grade astrocytomas [8%], two of nine mid-grade astrocytomas
[22%], and 17 of 20 glioblastoma multiforme (GBM) speci-
mens [85%]) and was undetectable in normal human brain
(zero of ﬁve). Thus, expression of p75
NTR is a common event
in GBM. To demonstrate that the presence of p75
NTR in these
patient specimens confers an increased migratory ability,
short-term cultures of these samples were analyzed in
transwell motility assays. The percentage of cells positive
for p75
NTR in the original population was determined by
immunostaining and compared to the percentage of p75
NTR-
positive cells in the migratory population (i.e., those cells that
migrated to the underside of the transwell chamber during
the assay). As a positive control for this assay, a mixture of
25% U87p75 cells and 75% U87pcDNA cells were used as
input. At completion of the control assay, the migratory
population contained approximately 50% p75
NTR-positive
cells (Figure 6C), as expected from initial experiments that
demonstrated that p75
NTR-positive cells migrate at a greater
Figure 4. Expression of p75
NTR in the U87 and U251N Glioma Cell Lines Dramatically Increases Invasion In Vivo
U87 or U251N human glioma cells stably transfected with the empty pcDNA vector (U87pcDNA [A] or U251NpcDNA [C]) or the p75
NTR-expression vector
(U87p75 [B] or U251NpcDNA [D]) were implanted into the brains of SCID mice and allowed to grow for 28 d. The mice were sacrificed, and frozen brain
sections were stained with antibodies against human nuclei (left) and human p75
NTR (right). Boxed areas indicate the region shown in the panel below,
thus magnification increases from top to bottom; scale bars in (A) and (B) represent 100 lm, 50 lm, and 25 lm; and scale bars in (C) and (D) represent
200 lm and 100 lm. Implantation of U87 glioma cells stably transfected with the empty pcDNA vector led to the formation of well-circumscribed
tumors that were p75
NTR negative (A). In sharp contrast, implantation of U87 glioma cells ectopically expressing p75
NTR led to the formation of tumors
with highly infiltrative edges (B). Similar results were seen in three independent experiments with six animals in each group. U251NpcDNA glioma cells
were generally more invasive than U87pcDNA cells upon implantation into the brains of SCID mice, and formed tumors with finger-like projections
extending into the surrounding normal brain (C); nevertheless, ectopic expression of p75
NTR in U251N cells dramatically increased the invasiveness of
these cells in vivo with isolated individual tumor cells being found distant from the main tumor mass (D). Similar results were seen in all ten animals in
each group.
doi:10.1371/journal.pbio.0050212.g004
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NTR-negative cells (Figure 3E and 3F).
Similar effects were observed with the glioma patient speci-
mens. The percentage of p75
NTR-positive cells in the
migratory population compared to the original population
was increased by 40%–100% (Figure 6C), demonstrating that
the p75
NTR-positive cells within the glioma patient samples
are more migratory than the p75
NTR-negative glioma cells.
p75
NTR Expression Results in Cytoskeletal Rearrangement
and Changes in RhoA Activity
During the in vitro growth stage of the serial in vivo–
selection procedure, we observed that the invasive glioma
cells had striking morphological differences to the ‘‘tumor’’
cells. To examine the morphology of these cells, ﬂuorescent
staining of the actin cytoskeleton was performed. Staining of
the actin cytoskeleton using rhodamine phalloidin revealed
cells with numerous ﬁlamentous protrusions present only in
the invading population (Figure 7A). Similarly, we found that
expression of p75
NTR alone induced structural rearrange-
ment of the actin cytoskeleton similar to that of the in vivo–
selected invasive cells (Figure 7B). Because the small
molecular weight GTPase RhoA is a potential downstream
readout from p75
NTR that may help contribute to the distinct
phenotype, we examined the effect of RhoA. Expression
studies in HEK293 cells demonstrated that in the absence of
ligand, p75
NTR constitutively activated Rho, whereas ligand
binding leads to a decrease in the levels of active Rho [27]. In
addition, Gehler et al. [49] have shown that neurotrophin-
bound p75
NTR induces growth cone ﬁlopodia through the
modulation of RhoA and that neurotrophin binding is
necessary and sufﬁcient to regulate ﬁlopodia dynamics. We
found that concomitant with the changes in actin cytoskele-
ton, cells expressing p75
NTR had reduced RhoA activity
(Figure 7C and 7D).
Discussion
Human malignant gliomas are highly invasive tumors. This
highly invasive nature associates theses tumors with an
extremely poor prognosis owing to recurrence of the tumor
outside the margin of therapeutic resection [50]. Invasion of
Figure 5. p75
NTR-Induced Glioma Invasion Is Neurotrophin Dependent
(A) U87 human glioma cells stably transfected with wild-type p75
NTR (red), the neurotrophin binding mutant p75CRD
105 (green), and p75CRD
130 (blue)
or pcDNA empty vector (yellow) were examined for cell surface expression of p75 receptors by flow cytometry using the p75-specific primary antibody
and an Alexa 448–conjugated secondary antibody.
(B) Expression of BDNF in the conditioned medium (blue bar) and the total cell lysate (yellow bar) of U87 glioma cells expressing pcDNA (control),
p75
NTR (p75), CRD 105, and CRD 130 were analyzed by ELISA. BDNF was found in the cell-associated fraction of U87 cells expressing p75, but not in the
cells expressing the neurotrophin binding mutants CRD
105 or CRD
130.
(C) U87 cells expressing wild-type p75
NTR, neurotrophin binding mutant CRD
105, or CRD
130 were implanted into the brains of SCID mice and allowed to
grow for 28 d. The mice were sacrificed, and frozen brain sections were stained with antibodies against human nuclei (ANA; top row) and human p75
NTR
(bottom row). Scale bars in (C) represent 100 lm. Implantation of either U87 glioma cells stably transfected with CRD
130 or CRD
105 vector, in contrast to
the highly infiltrative edges of U87p75, led to the formation of well-circumscribed tumors. Similar results were seen in three independent experiments
with six animals in each group. Expression of neurotrophin binding mutants of p75
NTR negates p75-induced glioma invasion.
doi:10.1371/journal.pbio.0050212.g005
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changes that make these cells distinct from their noninvasive
counterparts. Speciﬁcally, these glioma cells activate a
number of coordinate cellular programs that involve the
regulation of many molecules, including adhesion molecules,
extracellular matrix constituents, proteases, cytoskeleton
components, and signaling molecules. Altered regulation of
any of these constituents may lead to changes in glioma cell
migration and invasion. Although numerous molecules have
been implicated in the migration and invasion of gliomas,
what triggers glioma cells to leave the main tumor mass and
invade into the normal brain is not well understood. To this
end, we have developed a serial in vivo–selection paradigm to
isolate highly invasive glioma cells from a human glioma cell
Figure 6. p75
NTR Is Present and Confers Increased Migratory Ability in Glioblastoma Multiforme Patient Specimens
(A) Expression of p75
NTR (brown) was examined by immunohistochemistry in normal human brain specimens (zero of five) and GBM patient specimens
(17 of 20). Representative samples are shown. Slides were counterstained with hematoxylin (blue). Scale bars from top to bottom represent 100 lm, 50
lm, and 25 lm.
(B) p75
NTR mRNA and protein were assessed in glioblastoma patient specimens (GBM) and normal human brain (N). Human dorsal root ganglia (DRG)
were used as a positive control. GAPDH was used as an internal loading control for RT-PCR. b-Tubulin was used as a protein loading control. Neuronal
(neurofilament 70: [NF70]) and glial (glial fibrillary acid protein [GFAP]) markers in patient specimens are shown.
(C) p75
NTR-positive glioma cells from patient specimens have an increased migratory ability. Migration of in vitro–cultured glioma patient specimens
was evaluated using transwell motility assays. As a positive control for the assay, a mixture of 25% U87p75 cells and 75% U87pcDNA cells were analyzed
at the same time as the patient samples. For both the control sample and the patient samples, the percentage of p75
NTR-positive cells in the migratory
population (cells that migrated to the underside of the transwell) was increased compared to the percentage of p75
NTR-positive cells in the original
population. Values shown are the mean 6 SEM. A single asterisk (*) indicates p , 0.05; double asterisks (**) indicate p , 0.01; and triple asterisks (***)
indicate p , 0.001 (t-test within a given sample).
doi:10.1371/journal.pbio.0050212.g006
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similar approach has been used to successfully assess the
global gene expression proﬁle of both melanoma and breast
cancer metastasis [7,8]. Using this strategy, we identiﬁed and
veriﬁed genes that were up-regulated in the invading glioma
cells. One of the most differentially expressed genes encodes
the neurotrophin receptor p75
NTR that is the focus of this
study. We provide the ﬁrst evidence both in vitro and in vivo
that p75
NTR is a major mediator of glioma migration and
invasion.
In recent years, there has been a growing importance of the
neurotrophin signaling axis in cancer. Speciﬁcally, there is
increasing evidence that the neurotrophic receptor tyrosine
kinase TrkB, sometimes in conjunction with its primary
ligand BDNF, is over-expressed in a variety of human cancers,
ranging from neuroblastomas to pancreatic ductal adeno-
carcinomas [51–55]. Here, we present data that the pan-
neurotrophin receptor p75
NTR is expressed in malignant
glioma and is a major contributor to their highly invasive
nature. Although a universal role for p75
NTR in cancer has
not been established, recent studies implicate p75
NTR in the
metastatic progression of melanoma, and speciﬁcally in those
tumors that metastasize to the brain [43,46,56]. Conversely,
p75
NTR expression has been linked to the progression of
prostate cancer, but in this cancer, p75
NTR,w h i c hi s
expressed in normal prostate epithelia, is lost upon trans-
formation [45]. The divergence observed in the tumor
progression of these two distinct tumors can likely be
explained by the presence of Trk. In prostrate tumor cells,
Trk expression is retained and mediates proliferation [42,57],
whereas p75
NTR-induced invasion in melanoma is independ-
ent of Trk expression [58]. Thus the recurring theme emerges
that p75
NTR function is cell-type speciﬁc (even in cancer) and
must be independently determined for each cellular context.
Here, we have shown that p75
NTR-induced glioma invasion is
also Trk independent with neither mRNA nor protein for the
Trk receptors expressed by the invading glioma cells. Further
supporting the Trk independence of p75
NTR-mediated
glioma invasion is the ﬁnding that treatment of the invasive
cells with cleavage-resistant pro-NGF (which cannot bind Trk;
Figure S2) also enhanced the migration of invading glioma
cells.
Tumor cells can survive by means of an autostimulatory
(autocrine) signaling loop, such as that mediated by TrkB and
BDNF, or through a paracrine cross-communication with
their environment. In brain metastatic melanoma, normal
brain tissue adjacent to the melanoma displays increased
neurotrophin expression [56], making it tempting to spec-
ulate that the metastatic melanoma uses the neurotrophin-
rich nervous system as a paracrine mediator of invasion. It
has similarly not escaped our attention that the neurotrophin
environment of the brain may provide an extremely advanta-
geous milieu for an invading glioma cell. Our data show that
the p75
NTR-expressing glioma cells are ligand responsive and
may therefore use neurotrophins available in the brain
environment to their advantage. In addition, we show that
the invasive nature of glioma cells expressing p75
NTR is
negated when these cells express mutant p75
NTR receptors
that no longer bind to neurotrophin.
The concept of p75
NTR playing a role in migration is not
unprecedented. Neural crest cells, the most extensively
studied population of migrating cells in the nervous system,
express p75
NTR even before they commit to any cell differ-
entiation lineage [59]. In addition, Anton et al. [35] showed
that stimulation of the p75
NTR by NGF allowed Schwann cells
to migrate on peripheral nerves, and examination of p75
 / 
mice showed severe impairment of Schwann cell migration,
with no response to NGF [26]. More recently, the Hempstead
laboratory [46] has shown that activation of p75
NTR with NGF
or pro-NGF (the unprocessed, precursor form of NGF) caused
migration of melanoma cells and increased expression of
p75
NTR correlated with advanced stages and invasive poten-
Figure 7. Ectopic Expression of p75 Results in Actin Cytoskeletal
Rearrangement and Decreased RhoA Activity
(A) Actin staining of tumor (left) and invasive cells (right) shows striking
cytoskeletal rearrangement in the invading glioma cells. Actin cytoske-
leton was visualized by staining fixed and permeabilized cells with
rhodamine phalloidin (red), and cell nuclei were visualized with DAPI
(blue). Numerous filamentous protrusions are seen in the invading
glioma cells.
(B) p75
NTR is sufficient to induce cytoskeletal rearrangement of glioma
cells. U87pcDNA (left) and U87p75 (right) cells were fixed, permeabilized,
and stained with rhodamine phalloidin (red) and DAPI to visualize the
nucleus (blue).
(C) p75
NTR expression results in decreased RhoA activity. RhoA activity
was determined in U87pcDNA (pcDNA) and U87p75 (p75
NTR) by RhoA
pulldown assay using a GST fusion protein containing RBD-rhotekin that
binds only to activated (GTP-bound) RhoA. Western blots using total cell
lysates were performed for p75
NTR, RhoA, and b-actin (used as a protein
loading control).
(D) Bar graph shows quantitation of activated RhoA (Rho-GTP) as
compared to total RhoA in both U87pcDNA and U87p75. Values shown
are the mean 6 SEM from four independent experiments.
doi:10.1371/journal.pbio.0050212.g007
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underlying mechanism of p75-induced migration of melano-
ma cells is not understood; however, p75
NTR has been shown
to interact with the actin cytoskeleton [46]. The small GTPase
RhoA is a downstream effector of p75
NTR [27,28]. The
capability of p75
NTR to modulate the activity of RhoA
provides a reasonable explanation as to how p75
NTR
regulation might result in changes in cellular architecture
of glioma cells. We found that concomitant with increased
glioma invasion, glioma cells expressing p75
NTR showed
reduced RhoA activity and striking actin rearrangement.
Previous molecular characterization has deﬁned genetic
changes between low-grade and high-grade glioma [61–67]. In
addition, molecular signatures of glioblastoma subtypes have
been identiﬁed, including proﬁles of primary and secondary
glioblastoma subgroups [68–70]. On the other hand, very little
is known with respect to the transcriptional proﬁles of
invading glioma cells. Studies have been performed using
laser capture microdissection in patient specimens to collect
the invasive cells and the cells from the main tumor mass.
Although this approach has been used successfully to identify
invasion-related genes [9], these experiments make the
assumption that the invasive cells at the leading edge of the
tumor have distinct proﬁles from the main tumor mass and
that only tumor cells at the invading edge express genes
important for migration and invasion. Yet, within the highly
heterogeneous environment of a glioblastoma, in which there
are many hypoxic and necrotic regions, it would be easy to
envision that tumor cells experiencing oxidative stress would
activate mechanisms enabling them to move to a more
favorable environment. As such, some genes may not be
identiﬁed using such an approach. Indeed, our data show that
in addition to p75
NTR-expressing glioma cells at the invasive
edge of patient tumors, histological analysis identiﬁed
p75
NTR-positive glioma cells in regions of the tumor not
adjacent to normal brain parenchyma. An alternative
explanation for the appearance of p75
NTR-positive glioma
cells is that p75
NTR promotes survival of glioma cells in vivo,
though we did not ﬁnd that p75
NTR conferred a survival
advantage in vitro. Additionally, reports of ‘‘stem-like’’ cells
in brain tumors suggest that brain tumors arise from the
transformation of neural stem cells [71–73], and when
implanted into the brains of SCID mice, these cells form
highly invasive tumors [16,74,75]. Whether these brain tumor
stem cells express p75
NTR is an important question for future
studies, especially given that nestin-positive, p75
NTR-positive
cells have been identiﬁed in the subventricular zone of the
adult brain [76].
Identiﬁcation of key regulatory proteins of glioma invasion
is extremely important clinically because this will be used to
provide therapeutically relevant targets to prevent malignant
glioma recurrence at the invasive margin of gliomas [4].
H e r e i n ,w ep r e s e n tt h eﬁ r s te v i d e n c et h a tp 7 5
NTR is
important in glioma migration, and the mere expression of
p75
NTR is sufﬁcient to impart a dramatic invasive behavior on
genetically distinct glioblastomas. Because p75
NTR has also
been implicated in the progression of melanoma, and
speciﬁcally in those tumors that metastasize to the brain
[33,46,77], therapies that target p75
NTR, p75
NTR downstream
effectors, or their ligands may not only be beneﬁcial for
malignant glioma, but may target other metastatic diseases.
Materials and Methods
Cell culture. The human glioma cell line U87 was obtained from
the American Type Culture Collection (http://www.atcc.org). The
human glioma cell lines U251N and SF767 were kind gifts from V. W.
Yong (University of Calgary, Calgary, Alberta, Canada) and M. Berens
(Barrow Neurological Institute, Phoenix, Arizona, United States),
respectively. All cells were maintained in complete medium (Dulbec-
co’s Modiﬁed Eagle’s Medium [DMEM] F12 supplemented with 10%
heat-inactivated fetal bovine serum, 1% antibiotic/antimycotic, 0.1
mM nonessential amino acids, 2 mM L-glutamine and 1 mM sodium
pyruvate (GIBCO BRL, http://www.invitrogen.com)] at 37 8Ci na
humidiﬁed 5% CO2 incubator. Cells were passaged by harvesting with
trypsin when they reached 80%–90% conﬂuence. Stable transfectants
of U87 and SF767 cells were maintained in the same medium, with
the addition of 400 lg/ml G418 or 200 lg/ml hygromycin, respectively
(Invitrogen, http://www.invitrogen.com).
Generation of plasmids. The GFP expression vector was pGFP-N1
from Clontech (http://www.clontech.com). The human p75
NTR ex-
pression vector was constructed as described previously [46]. The
expression plasmids containing the p75
NTR mutants were constructed
either by subcloning of PCR fragments containing the desired p75
NTR
sequences (for p75CRD
130 construct) or by PCR-based site-directed
mutagenesis (for the p75CRD
105 constructs). Primers used for the
construction of the mutants were: p75CRD
105 primers (sense: 59-CGG
GCT CGG GCC GCT CGA GCG GCC TCG TGT TC–39; antisense: 59-
GAA CAC GAG GCC GCT CGA GCG GCC CGA GCC CG–39) and
template p75WT [46]; p75CRD
130 primers (sense: 59- GAA GAT CTC
CAA GGA GGC ATG CCC CAC AGG CC–39; antisense: 59-CTC ACT
ATA GGT CGA CCG GAA TTC G– 39) and template pT3/T7-p75. The
original templates were from B. Hempstead (p75WT; Cornell
University Medical College) and M. Chao (pT3/T7-p75; New York
University School of Medicine, New York, New York, United States).
The sequences of all the mutant expression plasmids were conﬁrmed
prior to stable transfection. The p75
NTR-speciﬁc siRNA expression
vector was constructed by ligating a double-stranded hairpin
oligonucleotide: 59-GAT CCG AGG ATC GGA GGC TTG TCA TTC
AAG AGA TGA CAA GCC TCC GAT CCT CTT TTT TGG AAA-39,
containing a p75
NTR-speciﬁc siRNA sequence (underlined), into the
pSilencer 2.1-U6 hygro vector (Ambion, http://www.ambion.com). The
negative control pSilencer vector, containing a random siRNA with
limited homology to any known human, mouse, or rat sequences, was
obtained from Ambion.
Transfection of glioma cell lines. Cells to be transfected were
seeded at 2 3 10
5 cells/well of a six-well plate and incubated at 37 8C
overnight in complete media. Vector DNA was introduced to the cells
using FuGENE 6 transfection reagent (Roche Diagnostic, http://www.
roche.com) according to the manufacturer’s instructions. The cells
were then incubated at 37 8C overnight; and the following day, the
medium was changed to fresh complete medium containing an
antibiotic (concentration determined by toxicity curve for cell line)
to select for those cells that had taken up the vector. The cells were
then grown under antibiotic selection until the wells were conﬂuent.
For GFP transfection, transfected cells were identiﬁed by ﬂuorescent
microscopy and GFP expression of greater than 95% was obtained by
ﬂuorescence-activated cell sorting. For p75
NTR,p 7 5 C R D
105,
p75CRD
130, and p75
NTR-siRNA transfection, transfected cells were
identiﬁed by RT-PCR and Western blot.
Animals. Six- to 8-wk-old female SCID mice were purchased from
Charles River Laboratories (http://www.criver.com). The animals were
housed in groups of three to ﬁve, maintained on a 12-h light/dark
schedule with a temperature of 22 8C 6 1 8C and a relative humidity
of 50% 6 5%. Food and water were available ad libitum. All
procedures were reviewed and approved by the University of Calgary
Animal Care Committee.
In vivo selection of invasive glioma cells. Actively growing U87 cells
expressing GFP and neomycin resistance genes (U87GFP) were
harvested by trypsinization, washed, and resuspended in sterile PBS
(137 mM NaCl, 8.1 mM Na2HPO4, 2.68 mM KCl, and 1.47 mM
KH2PO4 [pH 7.5]). These cells were implanted intracerebrally into the
right putamen of SCID mice (1310
5 cells/mouse) at a depth of 3 mm
through a scalp incision and a 0.5-mm burr hole made 1.5–2 mm right
of the midline and 0.5–1 mm posterior to the coronal suture.
Stereotactic techniques were described previously [77]. Tumor
formation was allowed to proceed for 21þ days, depending on the
health of the mouse and the type of cells injected. The mice were then
sacriﬁced and the brain examined using ﬂuorescence. The brain was
divided in half coronally; one half was used for frozen sections and
the other used for tissue culture. For tissue culture, the hemisphere
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hemisphere, and the two pieces were treated individually. The tissue
was minced into small pieces and dissociated with trypsin and DNase
Ia t3 78C. The tissue suspension was then forced through a 100-lm
mesh, and the resulting cell suspension was centrifuged and
resuspended in complete medium containing 400 lg/ml G418 to
select for the GFP-transfected tumor cells. Cells obtained from the
tumor mass were labeled as ‘‘tumor’’ cells, and those from the
contralateral hemisphere were labeled as ‘‘invasive’’ cells. Tumor and
invasive cells were then reinoculated into SCID mice, and the
procedure was repeated.
RT-PCR. Total cellular RNA was extracted from subconﬂuent cells
using Trizol Reagent (Invitrogen) and DNase-treated using DNA-free
(Ambion). The reverse transcription reaction took place in a buffer of
10 mM Tris-HCl (pH 9.0), 50 mM KCl, and 1.5 mM MgCl2, and
contained 3 lg of total RNA, 25 units of RNAguard RNase inhibitor, 1
mM each of deoxynucleoside triphosphates, 100 ng of pd(N)6 random
hexanucleotide primers (Amersham Biosciences, http://www.
amersham.com), and 200 units of Superscript II reverse transcriptase
(Invitrogen). The PCR ampliﬁcation reaction was carried out in the
same buffer and contained 1 ll of the cDNA synthesis reaction, 80 lM
each of deoxynucleoside triphosphates, 1 unit of Taq DNA polymer-
ase (Amersham Biosciences), and 0.1 lM each of p75
NTR-speciﬁc
primers (forward: 59-CGT ATT CCG ACG AGG CCA ACC-39; reverse:
59-CCA CAA GGC CCA CAA CCA CAG C-39), p75CRD
105-speciﬁc
primers (forward: 59-CGG GCT CGG GCC GCT CGA GCG GCC TCG
TGT TC-39; reverse primer: 59-GAA CAC GAG GCC GCT CGA GCG
GCC CGA GCC CG-39), p75CRD
130-speciﬁc primers (forward: 59-GAA
GAT CTC CAA GGA GGC ATG CCC CAC AGG CC-39; reverse
primer: 59-CTC ACT ATA GGT CGA CCG GAA TTC G-39), or 0.2 lM
each of GAPDH-speciﬁc primers (forward primer: 59-CGG AGT CAA
CGG ATT TGG TCG TAT-39; reverse primer: 59-AGC CTT CTC CAT
GGT GGT GAA GAC-39). The ampliﬁcation consisted of 35 cycles of
45 s at 94 8C, 30 s at 63 8C, and 45 s at 72 8C, followed by a 7-min
extension at 72 8C after the last cycle. The reaction products were
then resolved on a 1% agarose gel containing ethidium bromide.
Western blotting. Total cellular lysates were obtained by gentle
rocking in lysis buffer (20 mM Tris [pH 8.0], 137.5 mM NaCl, 10%
glycerol, 1% Nonidet P-40, 25 lg/ml aprotinin, 10 lg/ml leupeptin, 3
mM sodium orthovanadate, 1 mM PMSF) at 4 8C. Protein extracts of
human glioma biopsies were obtained by immersing the samples in
ice-cold extraction buffer (50 mM Tris [pH 7.6], 200 mM NaCl, 10 mM
CaCl2, 1% Triton X-100) followed by homogenization on ice. Cellular
debris was removed by centrifugation, and protein quantiﬁcation was
performed using the bicinchoninic acid (BCA) assay (Pierce Bio-
technology, http://www.piercenet.com). Proteins were resolved on
10% SDS-PAGE gels, and Western blots were performed using the
following primary antibodies: rabbit polyclonal anti-human p75
NTR
(Promega, http://www.promega.com), goat polyclonal anti-pyruvate
kinase (Chemicon, http://www.chemicon.com), mouse monoclonal
anti-neuroﬁlament, 70 kDa (Chemicon), mouse monoclonal anti-glial
ﬁbrillary acid protein (ChemiconA), or mouse monoclonal anti-b-
tubulin (Sigma-Aldrich, http://www.sigmaaldrich.com). The appropri-
ate HRP-conjugated secondary antibody (Pierce Biotechnology) was
used and visualized using enhanced chemiluminescence (Amersham
Biosciences).
Flow cytometric analysis of p75
NTR expression. Cells were collected
using Puck’s EDTA at 37 8C and then washed in PBS containing 1 mM
EDTA (PBS/EDTA). Cells were then treated with monoclonal anti-
p75
NTR, clone ME20.4 (which recognizes the extracellular domain;
Upstate Biotechnology, http://www.upstate.com), diluted 1:250 in PBS/
EDTA for 30 min on ice. The negative control sample was incubated
in only PBS/EDTA. After washing with PBS/EDTA, cells were treated
with Alexa 488–conjugated goat anti-mouse IgG (Invitrogen Molec-
ular Probes, http://probes.invitrogen.com) diluted 1:500 in PBS/EDTA
for 30 min on ice. Cells were then washed with PBS/EDTA,
r e s u s p e n d e di nP B S / E D T A ,a n da n a l y z e do naF A C S c a nﬂ o w
cytometer (Becton, Dickinson and Company, http://www.
bdbiosciences.com).
Enzyme-linked immunosorbent assay. Cells were allowed to
condition the medium for 5 d. The conditioned medium was then
collected, centrifuged, and ﬁltered through a 0.2-lm syringe ﬁlter
(VWR International, http://www.vwr.com). The remaining cells were
washed with ice-cold PBS, and total cellular lysates were extracted as
described for Western blot. Protein quantiﬁcation was performed
using the BCA assay (Pierce Biotechnology) and BDNF enzyme-linked
immunosorbent assays (ELISAs) (R&D Systems, http://www.
rndsystems.com) were performed as per the company protocol.
Brieﬂy, MaxiSorp ELISA plates (Nalge Nunc International, http://
www.nalgenunc.com) were coated with monoclonal anti-human
BDNF (R&D Systems), nonspeciﬁc binding was blocked, and serial
dilutions of recombinant human BDNF (Sigma-Aldrich), equal
volumes of conditioned medium, or equal quantities of lysate were
added. Bound antigen was detected using the corresponding
biotinylated antibody, streptavidin HRP, and a tetramethylbenzidine
substrate (R&D Systems).
Circular monolayer migration assay. Migration assays were
performed using a microliter-scale radial monolayer migration assay
as described by Berens et al. [78]. Brieﬂy, ten-well Teﬂon-masked
microscope slides were coated with 20 lg/ml laminin. Cells were
seeded through a cell sedimentation manifold (Creative Scientiﬁc
Methods, http://www.cre8ive-sci.com) at 2,000 cells/well to establish a
circular 1-mm diameter conﬂuent monolayer. Once the sedimenta-
tion manifolds were removed, cells were given complete medium
containing the appropriate treatment. A digital image of the cells was
taken (before migration ¼ 0 h) using a Zeiss Axiovert 200M inverted
ﬂuorescent microscope (Carl Zeiss, http://www.zeiss.com). The cells
were then incubated in a humidiﬁed chamber at 37 8C and 5% CO2,
and a second digital image was taken 48 h later. Best-ﬁt circles were
drawn around the area covered by the cells at the 0-h and 48-h time
points and the actual cell area determined using Axiovision 4.2
imaging software (Carl Zeiss). Quantitative migration scores were
calculated as the increase in the area covered by the cells beyond the
initial area of the cells.
In vitro invasion assay. Matrigel (BD Bioscience, Mississauga,
Ontario, Canada) was diluted with two parts of cold serum-free
medium, layered onto an 8-lm pore-size transwell chamber (BD
Bioscience, http://www.bdbiosciences.com), and incubated at room
temperature for 1 h. The wells were then rinsed with serum-free
medium. The coated chambers were placed into the wells of a 24-well
tissue culture plate containing 500 ll of media with or without the
desired treatment. Serum-starved cells (2.5 3 10
4) were seeded into
each chamber, in a volume of 500 ll of the same medium contained in
the bottom of the well, and incubated at 37 8C for 48 h. The medium
was then removed from the chambers and cells scraped off the top of
the membrane using a PBS-soaked cotton-tipped swab. Cells were
ﬁxed to the bottom of the chamber with methanol, stained in
hematoxylin, and mounted on slides. Invasion was quantiﬁed by
counting the stained cells adherent to the lower side of the
membranes in ten ﬁelds (at 103 magniﬁcation) for each of three
chambers for each condition.
In vivo studies of p75
NTR overexpression in an intracranial glioma
model. Actively growing U87pcDNA, U87p75, U87CRD
105,
U87CRD
130, U251NpcDNA, and U251Np75 cells were implanted
intracerebrally into SCID mice as described previously [77]. Mice
were sacriﬁced weekly from day 14–42. At each time point, the brains
were removed, frozen in OCT compound (Tissue-Tek; Electron
Microscopy Sciences, http://www.emsdiasum.com), and cryosectioned
for examination by immunohistochemistry.
Immunohistochemistry. Frozen sections were air dried at room
temperature, ﬁxed with cold acetone, and then rinsed with PBS.
Parafﬁn sections were dewaxed and rehydrated using a xylene/
ethanol series followed by rinsing with PBS. Endogenous perox-
idases in the sections were inactivated with 0.075% H2O2/methanol,
and nonspeciﬁc binding was blocked with 10% normal goat serum
in PBS. The sections were then incubated with rabbit polyclonal
anti-human p75
NTR (Promega, http://www.promega.com) or mouse
monoclonal anti-human nuclei (Chemicon) in blocking buffer
overnight at 4 8C. Following washing with PBS, the appropriate
biotinylated secondary antibody (Vector Laboratories, http://www.
vectorlabs.com) was applied. Avidin-biotin peroxidase complexes
were then formed using the VECTASTAIN Elite ABC kit (Vector
Laboratories) and detected by addition of SIGMAFAST DAB (3,39-
diaminobenzidine tetrahydrochloride) (Sigma-Aldrich). The SIGMA-
FAST DAB was converted to a brown reaction product by the
peroxidase. Hematoxylin (for parafﬁn sections) and toluidine blue
(for frozen sections) were used as nuclear counterstains. Sections
were then dehydrated in an ethanol/xylene series and mounted with
Entellan (Electron Microscopy Sciences).
Immunocytochemistry. Coverslips were coated with a Collagen I (3
mg/ml; Vitrogen 100; Cohesion Technologies, http://www.
cohesiontech.com) and incubated overnight at 37 8C. Excess collagen
solution was aspirated, and cells were plated at 2310
5/mL in DMEM
culture medium (DMEM with 10% FBS, 6 mM L-glutamine, 100 lM
nonessential amino acids, 1 mM sodium pyruvate, 400 lg/ml G418)
and allowed to equilibrate overnight at 37 8C, 5% CO2. Coverslips
were then rinsed twice with PBS, ﬁxed in 3.7% formaldehyde diluted
in PBS for 10 min, and rinsed twice with PBS. Unpolymerized actin
was extracted for 3 min in CSK buffer (10 mM MES [pH 6.1], 138 mM
KCl, 3 mM MgCl2, 2 mM EGTA, 320 mM sucrose, 0.1% Triton X-100)
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(Invitrogen) was diluted 1:40 in 1% BSA/PBS and 200 ll of this
solution was added to each coverslip for 20 min at room temperature.
Coverslips were rinsed twice with PBS, counterstained with a 500 nM
solution of DAPI for 3 min, mounted in glycerol, and imaged with an
Olympus IX70 Delta Vision RT Microscope (http://www.olympus.co.
jp/en/) and the SoftWoRx software package.
Tumor tissue. Tumor and normal tissues were obtained from the
Canadian Brain Tumor Tissue Bank in London, Ontario, and
Foothills Hospital, Calgary, Alberta. Brieﬂy, tissue was taken during
surgery while patients were under a general anesthetic, and was
placed immediately in liquid nitrogen and stored at 80 8C or placed
in culture medium for establishment of short-term cultures. An
institutional ethics board approved the collection and use of all of the
surgical tissue used, and all of the patients gave signed informed
consent. The following tissues were studied: 20 GBMs, eight anaplastic
astrocytomas, one anaplastic oligodendroglioma, ﬁve astrocytomas,
ﬁve mixed oligoastrocytomas, one oligodendroglioma, and ﬁve
controls obtained during nontumor brain surgery.
Short-term culture of primary human glioma cells. Operative
samples of human gliomas were obtained during brain tumor surgery
and transported to the laboratory in culture medium. Short-term
cultures were then established. Brieﬂy, necrotic and connective tissue
and any blood clots were removed using forceps, and the remaining
tissue was washed in PBS and cut into pieces of approximately 1 mm
2.
The tissue was then incubated for 30 min at 37 8C in an enzyme
cocktail of trypsin (0.25%) and DNase I (10 lg/ml) in PBS. The
digested tissue was strained through a 100-lm mesh and washed with
PBS. The cells were then pelleted and washed with DMEM-F12 media.
Following lysis of red blood cells, the remaining cells were washed
with PBS, pelleted, resuspended in complete media containing 20%
FBS, and plated.
Transwell motility assay of primary human glioma cells. Primary
human glioma cells cultured for less than 3 wk were ‘‘serum-starved’’
by incubating them in medium containing only 1% FBS for 2 h at 37
8C and 5% CO2. Cells were then released from the culture dish using
Puck’s EDTA (1 mM EDTA, 10 mM HEPES, 5 mM KCl, 140 mM NaCl,
4 mM NaHCO3, and 6 mM dextrose [pH 7.3]) at 37 8C. Cells (2.5310
4)
suspended in 1% FBS medium were plated in eight-well chamber
slides (Nunc) and transwell chambers (Costar) coated with 20 lg/ml
laminin. Medium containing 1% FBS was placed below the chamber.
The cells were incubated at 37 8C and 5% CO2 for 6 h. The medium
was then removed from the chambers, and cells were ﬁxed with 4%
paraformaldehyde. The cells were then stained for human p75
NTR,a s
described for immunohistochemical staining, and counterstained
with hematoxylin. In the transwell chamber, cells that did not migrate
were scraped off the top of the membrane using a cotton-tipped
swab. Migration was quantiﬁed by counting the p75
NTR-positive
(brown) and p75
NTR-negative (blue) cells in the original population
(on the slide) or in the migratory population (adherent to the under
side of the transwell membrane) in ﬁve ﬁelds (at 203 magniﬁcation)
for each of four chambers.
Supporting Information
Figure S1. In Vivo–Selected U251 Invasive Cells Express p75
NTR
U251 human glioma GFP-expressing cell line was implanted into the
brains of SCID mice; and 4–6 wk later, the mice were sacriﬁced. The
ipsilateral side of the brain (containing a grossly visible tumor) was
separated from the contralateral side (containing only isolated
invasive glioma cells) and both were grown in culture. These
noninvasive (tumor [U251T]) and highly invasive (invasive [U251R])
cells were reimplanted and the process repeated to select for
increasingly noninvasive or invasive glioma cells. Through the serial
in vivo selection, highly invasive U251 glioma cells were isolated.
Western-blot analysis of p75
NTR expression in tumor and invasive
U251 human glioma cells shows a dramatic increase in endogenous
p75
NTR expression in the U251 invasive cells as compared to the U251
tumor cells. U87 tumor (U87T) and invasive (U87R) cells were used
for comparison (A). The invasive U251 cells, which endogenously
express p75
NTR, showed a signiﬁcant increase in migration (B) and
invasion (C) compared to U251 tumor cells. Double asterisks(  )
indicate p , 0.001 (tumor vs. invasive, paired t-test). Values shown are
the mean 6 standard error of the mean (SEM) from three
independent experiments.
Found at doi:10.1371/journal.pbio.0050212.sg001 (136 KB TIF).
Figure S2. Invasive Glioma Cells Expressing p75
NTR Increase
Migration in Response to Cleavage-Resistant Form of pro-NGF
Treatment of invasive cells with a cleavage-resistant form of pro-NGF
signiﬁcantly increased migration at concentrations as low as 1 ng/ml.
Values shown are the mean 6 SEM for a single experiment. Similar
results were seen in three independent experiments Double asterisks
(**) indicate p , 0.01, and triple asterisks (***) indicate p , 0.001
versus control (one-way analysis of variance [ANOVA] with Bonfer-
roni post-test). Statistics were done on the experiment shown.
Found at doi:10.1371/journal.pbio.0050212.sg002 (58 KB TIF).
Figure S3. Autocrine BDNF Is Bound to the Cell Surface of p75
NTR-
Expressing U87 Cells
BDNF expression was conﬁrmed by RT-PCR (A). The amount of
BDNF protein contained in the conditioned medium (B) or cell
associated before and after treatment with a cell surface-stripping
reagent (C) was measured by ELISA in cells expressing either empty
vector (pcDNA) or a p75
NTR-expression vector (p75), U87 pcDNA and
U87p75. Values shown are the mean 6 SEM from a single experi-
ment; triple asterisks (***) indicate p , 0.001 U87p75 compared to
pcDNA; triple pluses (þþþ) indicate p , 0.001 U87p75 before and
after cell surface stripping. Similar results were seen in three
independent experiments.
Found at doi:10.1371/journal.pbio.0050212.sg003 (153 KB TIF).
Figure S4. Down-Regulation of p75
NTR Expression Using RNAi
Decreases Migration and Invasion of In Vivo–Selected U87 Invasive
Glioma Cells
(A) RT-PCR (GAPDH used as a loading control) and (B) Western blot
(pyruvate kinase used as a loading control) conﬁrm down-regulation
of p75
NTR in the in vivo–selected invasive glioma cells, transiently
transfected with a p75
NTR-speciﬁc siRNA. (C) Down-regulation of
p75
NTR levels by siRNA in the in vivo–selected invasive glioma cells
signiﬁcantly reduces their circular migration and transwell invasion.
Values shown are the mean 6 SEM from four independent experi-
ments. Double asterisks (**) indicate p , 0.01 versus random siRNA
transfected cells (paired t-test).
Found at doi:10.1371/journal.pbio.0050212.sg004 (136 KB TIF).
Figure S5. U87p75 Glioma Cells Are Found Substantial Distances
from the Main Tumor Mass
To further illustrate the invasive nature of the p75
NTR-expressing
glioma cells, serial sections of brains from animals implanted with
either pcDNA or p75
NTR-expressing U87 glioma cells were stained
using a human nuclear-speciﬁc antibody. U87p75 glioma cells were
found substantial distances from the main tumor mass; right panel
shows whole-brain sections posterior to the main tumor. (First two
panels are the same as Figure 4).
Found at doi:10.1371/journal.pbio.0050212.sg005 (1.1 MB TIF).
Acknowledgments
We thank Z. Q. Shi, H. Muzik, M. Slovack, and B. Sun at the University
of Calgary for their technical support and expertise. ALMJ was
supported by the Alberta Heritage Foundation for Medical Research
(AHFMR), Canadian Institute of Health Research, and Natural
Sciences and Engineering Research Council studentships. JJR was
supported by a postdoctoral fellowship from the Alberta Cancer
Board. IFP is an AHFMR Clinician Scientist. SMR is a scientist for the
AHFMR and holds a Canada Research Chair in Cancer Biology. AL
and LW were supported by postdoctoral fellowships from the
AHFMR. PAF and DLS share senior authorship of this paper.
Author contributions. SMR, PAF, and DLS conceived and designed
the experiments. ALMJ, XL, JJR, AL, and LW performed the
experiments. ALMJ, XL, JJR, AL, LW, SMR, PAF, and DLS analyzed
the data. MGH, IFP, BLH, and SMR contributed reagents/materials/
analysis tools. ALMJ and DLS wrote the paper. MGH and IFP supplied
clinical surgical tissue for investigation.
Funding. This work was supported in part by a generous donation
from the Clark H. Smith Family, and by grants from the Cancer
Research Society (SMR and PAF) and the Canadian Institute of
Health Research (PAF and DLS).The Southern Alberta Microarray
Facility provided support and infrastructure for the DNA microarray
experiments.
Competing interests. The authors have declared that no competing
interests exist.
PLoS Biology | www.plosbiology.org August 2007 | Volume 5 | Issue 8 | e212 1735
p75
NTR-Induced Invasion in GliomaReferences
1. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, et al. (1999)
Which glioblastoma multiforme patient will become a long-term survivor?
A population-based study. Ann Neurol 46: 183–188.
2. Senger D, Cairncross JG, Forsyth PA (2003) Long-term survivors of
glioblastoma: Statistical aberration or important unrecognized molecular
subtype? Cancer J 9: 214–221.
3. Giese A, Westphal M (1996) Glioma invasion in the central nervous system.
Neurosurgery 39: 235–250.
4. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration:
Invasion of malignant gliomas and implications for treatment. J Clin Oncol
21: 1624–1636.
5. Demuth T, Berens ME (2004) Molecular mechanisms of glioma cell
migration and invasion. J Neurooncol 70: 217–228.
6. Joy AM, Beaudry CE, Tran NL, Ponce FA, Holz DR, et al. (2003) Migrating
glioma cells activate the PI3-K pathway and display decreased susceptibility
to apoptosis. J Cell Sci 116: 4409–4417.
7. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, et al.
(2001) Glioma cell motility is associated with reduced transcription of
proapoptotic and proliferation genes: A cDNA microarray analysis. J
Neurooncol 53: 161–176.
8. Holtkamp N, Afanasieva A, Elstner A, van Landeghem FK, Konneker M, et
al. (2005) Brain slice invasion model reveals genes differentially regulated
in glioma invasion. Biochem Biophys Res Commun 336: 1227–1233.
9. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, et al. (2005) Gene
expression proﬁle of glioblastoma multiforme invasive phenotype points to
new therapeutic targets. Neoplasia 7: 7–16.
10. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Kaczmarek E, et al.
(2001) Death-associated protein 3 (Dap-3) is overexpressed in invasive
glioblastoma cells in vivo and in glioma cell lines with induced motility
phenotype in vitro. Clin Cancer Res 7: 2480–2489.
11. Mariani L, McDonough WS, Hoelzinger DB, Beaudry C, Kaczmarek E, et al.
(2001) Identiﬁcation and validation of P311 as a glioblastoma invasion gene
using laser capture microdissection. Cancer Res 61: 4190–4196.
12. Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of
metastasis reveals an essential role for RhoC. Nature 406: 532–535.
13. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. (2005) Genes that
mediate breast cancer metastasis to lung. Nature 436: 518–524.
14. Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H (1990) Molecular
cloning and neurotrophic activities of a protein with structural similarities
to nerve growth factor: Developmental and topographical expression in the
brain. Proc Natl Acad Sci U S A 87: 5454–5458.
15. Hallbook F, Ibanez CF, Persson H (1991) Evolutionary studies of the nerve
growth factor family reveal a novel member abundantly expressed in
Xenopus ovary. Neuron 6: 845–858.
16. Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell
survival by secreted proneurotrophins. Science 294: 1945–1948.
17. Rodriguez-Tebar A, Dechant G, Barde YA (1990) Binding of brain-derived
neurotrophic factor to the nerve growth factor receptor. Neuron 4: 487–
492.
18. Rodriguez-Tebar A, Dechant G, Gotz R, Barde YA (1992) Binding of
neurotrophin-3 to its neuronal receptors and interactions with nerve
growth factor and brain-derived neurotrophic factor. EMBO J 11: 917–922.
19. Chao MV (2003) Neurotrophins and their receptors: A convergence point
for many signalling pathways. Nat Rev Neurosci 4: 299–309.
20. Dechant G, Barde YA (2002) The neurotrophin receptor p75(NTR): Novel
functions and implications for diseases of the nervous system. Nat Neurosci
5: 1131–1136.
21. Kaplan DR, Miller FD (2003) Axon growth inhibition: Signals from the p75
neurotrophin receptor. Nat Neurosci 6: 435–436.
22. Roux PP, Barker PA (2002) Neurotrophin signaling through the p75
neurotrophin receptor. Prog Neurobiol 67: 203–233.
23. Hempstead BL (2002) The many faces of p75NTR. Curr Opin Neurobiol 12:
260–267.
24. Wang KC, Kim JA, Sivasankaran R, Segal R, He Z (2002) P75 interacts with
the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420:
74–78.
25. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, et al. (2004) Sortilin is
essential for proNGF-induced neuronal cell death. Nature 427: 843–848.
26. Bentley CA, Lee KF (2000) p75 is important for axon growth and Schwann
cell migration during development. J Neurosci 20: 7706–7715.
27. Yamashita T, Tucker KL, Barde YA (1999) Neurotrophin binding to the p75
receptor modulates Rho activity and axonal outgrowth. Neuron 24: 585–
593.
28. Yamashita T, Higuchi H, Tohyama M (2002) The p75 receptor transduces
the signal from myelin-associated glycoprotein to Rho. J Cell Biol 157: 565–
570.
29. DeFreitas MF, McQuillen PS, Shatz CJ (2001) A novel p75NTR signaling
pathway promotes survival, not death, of immunopuriﬁed neocortical
subplate neurons. J Neurosci 21: 5121–5129.
30. Bamji SX, Majdan M, Pozniak CD, Belliveau DJ, Aloyz R, et al. (1998) The
p75 neurotrophin receptor mediates neuronal apoptosis and is essential
for naturally occurring sympathetic neuron death. J Cell Biol 140: 911–923.
31. Troy CM, Friedman JE, Friedman WJ (2002) Mechanisms of p75-mediated
death of hippocampal neurons. Role of caspases. J Biol Chem 277: 34295–
34302.
32. Boyd JG, Gordon T (2001) The neurotrophin receptors, trkB and p75,
differentially regulate motor axonal regeneration. J Neurobiol 49: 314–325.
33. Song XY, Zhong JH, Wang X, Zhou XF (2004) Suppression of p75NTR does
not promote regeneration of injured spinal cord in mice. J Neurosci 24:
542–546.
34. Yamauchi J, Chan JR, Shooter EM (2004) Neurotrophins regulate Schwann
cell migration by activating divergent signaling pathways dependent on
Rho GTPases. Proc Natl Acad Sci U S A 101: 8774–8779.
35. Anton ES, Weskamp G, Reichardt LF, Matthew WD (1994) Nerve growth
factor and its low-afﬁnity receptor promote Schwann cell migration. Proc
Natl Acad Sci U S A 91: 2795–2799.
36. Yamashita T, Tohyama M (2003) The p75 receptor acts as a displacement
factor that releases Rho from Rho-GDI. Nat Neurosci 6: 461–467.
37. Dubreuil CI, Winton MJ, McKerracher L (2003) Rho activation patterns
after spinal cord injury and the role of activated Rho in apoptosis in the
central nervous system. J Cell Biol 162: 233–243.
38. Niederost B, Oertle T, Fritsche J, McKinney RA, Bandtlow CE (2002) Nogo-
A and myelin-associated glycoprotein mediate neurite growth inhibition by
antagonistic regulation of RhoA and Rac1. J Neurosci 22: 10368–10376.
39. Weis C, Wiesenhofer B, Humpel C (2002) Nerve growth factor plays a
divergent role in mediating growth of rat C6 glioma cells via binding to the
p75 neurotrophin receptor. J Neurooncol 56: 59–67.
40. Bhakar AL, Howell JL, Paul CE, Salehi AH, Becker EB, et al. (2003)
Apoptosis induced by p75NTR overexpression requires Jun kinase-
dependent phosphorylation of Bad. J Neurosci 23: 11373–11381.
41. Tysnes BB, Mahesparan R (2001) Biological mechanisms of glioma invasion
and potential therapeutic targets. J Neurooncol 53: 129–147.
42. Djakiew D (2000) Dysregulated expression of growth factors and their
receptors in the development of prostate cancer. Prostate 42: 150–160.
43. Herrmann JL, Menter DG, Hamada J, Marchetti D, Nakajima M, et al. (1993)
Mediation of NGF-stimulated extracellular matrix invasion by the human
melanoma low-afﬁnity p75 neurotrophin receptor: Melanoma p75 func-
tions independently of trkA. Mol Biol Cell 4: 1205–1216.
44. Marchetti D, Menter D, Jin L, Nakajima M, Nicolson GL (1993) Nerve
growth factor effects on human and mouse melanoma cell invasion and
heparanase production. Int J Cancer 55: 692–699.
45. Perez M, Regan T, Pﬂug B, Lynch J, Djakiew D (1997) Loss of low-afﬁnity
nerve growth factor receptor during malignant transformation of the
human prostate. Prostate 30: 274–279.
46. Shonukan O, Bagayogo I, McCrea P, Chao M, Hempstead B (2003)
Neurotrophin-induced melanoma cell migration is mediated through the
actin-bundling protein fascin. Oncogene 22: 3616–3623.
47. Walch ET, Albino AP, Marchetti D (1999) Correlation of overexpression of
the low-afﬁnity p75 neurotrophin receptor with augmented invasion and
heparanase production in human malignant melanoma cells. Int J Cancer
82: 112–120.
48. Yan H, Chao MV (1991) Disruption of cysteine-rich repeats of the p75
nerve growth factor receptor leads to loss of ligand binding. J Biol Chem
266: 12099–12104.
49. Gehler S, Gallo G, Veien E, Letourneau PC (2004) p75 neurotrophin
receptor signaling regulates growth cone ﬁlopodial dynamics through
modulating RhoA activity. J Neurosci 24: 4363–4372.
50. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, et al. (1996)
Adenovirus-mediated transfer of the p53 gene produces rapid and
generalized death of human glioma cells via apoptosis. Cancer Res 56:
694–699.
51. Aoyama M, Asai K, Shishikura T, Kawamoto T, Miyachi T, et al. (2001)
Human neuroblastomas with unfavorable biologies express high levels of
brain-derived neurotrophic factor mRNA and a variety of its variants.
Cancer Lett 164: 51–60.
52. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, et al. (2003) Mutational
analysis of the tyrosine kinome in colorectal cancers. Science 300: 949.
53. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, et al.
(2004) Suppression of anoikis and induction of metastasis by the neuro-
trophic receptor TrkB. Nature 430: 1034–1039.
54. Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, et al. (2001) Expression
of the neurotrophin receptor TrkB is associated with unfavorable outcome
in Wilms’ tumor. J Clin Oncol 19: 689–696.
55. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM (1994) Expression and
function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14:
759–767.
56. Menter DG, Herrmann JL, Marchetti D, Nicolson GL (1994) Involvement of
neurotrophins and growth factors in brain metastasis formation. Invasion
Metastasis 14: 372–384.
57. Pﬂug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D (1995) Expression of a
Trk high afﬁnity nerve growth factor receptor in the human prostate.
Endocrinology 136: 262–268.
58. Marchetti D, Parikh N, Sudol M, Gallick GE (1998) Stimulation of the
protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human
brain-metastatic melanoma cells. Oncogene 16: 3253–3260.
59. Stemple DL, Anderson DJ (1992) Isolation of a stem cell for neurons and
glia from the mammalian neural crest. Cell 71: 973–985.
60. Walsh GS, Krol KM, Crutcher KA, Kawaja MD (1999) Enhanced neuro-
PLoS Biology | www.plosbiology.org August 2007 | Volume 5 | Issue 8 | e212 1736
p75
NTR-Induced Invasion in Gliomatrophin-induced axon growth in myelinated portions of the CNS in mice
lacking the p75 neurotrophin receptor. J Neurosci 19: 4155–4168.
61. Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, et al. (2002) Molecular
classiﬁcation of human diffuse gliomas by multidimensional scaling analysis
of gene expression proﬁles parallels morphology-based classiﬁcation,
correlates with survival, and reveals clinically-relevant novel glioma subsets.
Brain Pathol 12: 108–116.
62. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, et al. (1999) Reactivation
of insulin-like growth factor binding protein 2 expression in glioblastoma
multiforme: A revelation by parallel gene expression proﬁling. Cancer Res
59: 4228–4232.
63. Kim S, Dougherty ER, Shmulevich I, Hess KR, Hamilton SR, et al. (2002)
Identiﬁcation of combination gene sets for glioma classiﬁcation. Mol
Cancer Ther 1: 1229–1236.
64. Ljubimova JY, Khazenzon NM, Chen Z, Neyman YI, Turner L, et al. (2001)
Gene expression abnormalities in human glial tumors identiﬁed by gene
array. Int J Oncol 18: 287–295.
65. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, et al. (2003)
Gene expression-based classiﬁcation of malignant gliomas correlates better
with survival than histological classiﬁcation. Cancer Res 63: 1602–1607.
66. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, et al. (2001)
Distinctive molecular proﬁles of high-grade and low-grade gliomas based
on oligonucleotide microarray analysis. Cancer Res 61: 6885–6891.
67. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, et al. (2000)
Identiﬁcation of differentially expressed genes in human gliomas by DNA
microarray and tissue chip techniques. Cancer Res 60: 6617–6622.
68. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, et al. (2005) Gene
expression proﬁling reveals molecularly and clinically distinct subtypes of
glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814–5819.
69. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, et al. (2005) Integrated
array-comparative genomic hybridization and expression array proﬁles
identify clinically relevant molecular subtypes of glioblastoma. Cancer Res
65: 1678–1686.
70. Tso CL, Freije WA, Day A, Chen Z, Merriman B, et al. (2006) Distinct
transcription proﬁles of primary and secondary glioblastoma subgroups.
Cancer Res 66: 159–167.
71. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, et al. (2002)
Human cortical glial tumors contain neural stem-like cells expressing
astroglial and neuronal markers in vitro. Glia 39: 193–206.
72. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH,
et al. (2003) Cancerous stem cells can arise from pediatric brain tumors.
Proc Natl Acad Sci U S A 100: 15178–15183.
73. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003)
Identiﬁcation of a cancer stem cell in human brain tumors. Cancer Res 63:
5821–5828.
74. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004)
Identiﬁcation of human brain tumour initiating cells. Nature 432: 396–401.
75. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation
and characterization of tumorigenic, stem-like neural precursors from
human glioblastoma. Cancer Res 64: 7011–7021.
76. Giuliani A, D’Intino G, Paradisi M, Giardino L, Calza L (2004) p75(NTR)-
immunoreactivity in the subventricular zone of adult male rats: Expression
by cycling cells. J Mol Histol 35: 749–758.
77. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, et al. (2001)
Reovirus as an oncolytic agent against experimental human malignant
gliomas. J Natl Cancer Inst 93: 903–912.
78. Berens ME, Rief MD, Loo MA, Giese A (1994) The role of extracellular
matrix in human astrocytoma migration and proliferation studied in a
microliter scale assay. Clin Exp Metastasis 12: 405–415.
PLoS Biology | www.plosbiology.org August 2007 | Volume 5 | Issue 8 | e212 1737
p75
NTR-Induced Invasion in Glioma